EP 250: Redefining rare disease realities with Sharon Terry of the Genetic Alliance [Re-run]

Value of the Information & Strength of the Argument

The episode provides valuable insights into the rare disease landscape from a highly experienced advocate. Sharon Terry’s arguments are well-founded, drawing on her extensive personal and professional experience. She effectively argues for a paradigm shift in how rare diseases are approached, advocating for public health subsidies and international collaboration. Her points about the inefficiencies of traditional clinical trial recruitment and the importance of patient-led biobanks are compelling and supported by concrete examples, such as recruiting 65 patients for a PXE trial in six weeks. The discussion is balanced, acknowledging challenges and counterarguments, such as the fragmentation of rare disease communities and the limitations of current incentives.

Scientific Rigor, Source Quality, Title Accuracy

Sharon Terry is a credible source, with over 30 years of experience in rare disease advocacy and policy. She co-founded the International Rare Disease Research Consortium and led the coalition that passed GINA. The episode references specific programs and papers, such as the iHope program and a publication on 1,000 sequenced children, but does not provide direct citations or URLs. The title accurately reflects the content, focusing on redefining rare disease realities through Sharon’s work. The discussion is based on expert opinion and personal experience rather than peer-reviewed research, but the information is consistent with known facts in the field.

The title accurately reflects the content, focusing on redefining rare disease realities through Sharon Terry's work and insights.

8/10

Sharon Terry is a recognized leader in rare disease advocacy with decades of experience. The episode is a re-run of an interview, providing expert opinions and personal experiences rather than primary research. The information is credible but based on individual perspective.

• 00:00Intro to The Genetics Podcast
• 00:59Welcome to Sharon and a discussion of the personal experience with rare disease that started her journey
• 03:47Reasons Sharon decided to establish the first layperson-led biobank
• 05:34Challenges with setting up the biobank infrastructure
• 07:00Balancing financial factors in a non-profit organization
• 09:30Recent patterns and future insight into rare disease drug discovery framework and regulation
• 15:32Barriers to widespread collaboration and cooperation in rare disease research, and why it should be approached from a public health perspective
• 18:12Background and experiences from the iHope Genetic Health program in low- to middle-income countries
• 24:44Sharon’s perspective on challenges with the Genetic Information Non-discrimination Act
• 28:49Sharon’s lessons learned in her patient advocacy and policy work, and her hopes for future legislation
• 33:04Sharon’s hopes for improved access to genetic testing and treatment for children in underserved communities
• 34:34How Sharon learned about rare diseases and genetics as a “homeschooling mom without a degree”
• 37:54Insights into how elements of spirituality can support advocacy work
• 40:18Closing remarks